How to Get Leqvio (Inclisiran) in Wyoming

What Is Leqvio and Why Is It Prescribed?

Leqvio is the brand name for inclisiran, a small interfering RNA (siRNA) that silences PCSK9 synthesis in the liver, which prevents PCSK9 from degrading LDL receptors and keeps circulating LDL-C low for roughly six months after each injection. The FDA approved inclisiran on December 22, 2021, for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical ASCVD who require additional LDL-C lowering on top of maximally tolerated statin therapy. 1

The ORION-10 trial (N=1,561, U.S. patients only) showed inclisiran 284 mg produced a 52.3% time-averaged reduction in LDL-C versus placebo at day 510, with P<0.001 for both co-primary endpoints. 2 The companion ORION-11 trial (N=1,617, European and South African patients) confirmed a 49.9% LDL-C reduction on the same schedule. 2 Adverse event rates in both trials were comparable to placebo, with injection-site reactions occurring in 2.6% of the inclisiran group. 2

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "In patients with very high-risk ASCVD who require further LDL-C lowering beyond statins and ezetimibe, PCSK9 inhibitors are recommended." 3 Inclisiran achieves that same LDL receptor effect via RNA interference rather than monoclonal antibody blockade, meaning dosing drops to twice yearly after the loading period.

Wyoming has a relatively sparse cardiology specialist base. For the approximately 578,000 residents statewide, telehealth fills a real access gap for specialty lipid management, and Wyoming law explicitly permits telehealth prescribing of prescription drugs including inclisiran. 4

Who Qualifies for Leqvio in Wyoming?

The FDA-approved indications are narrow. Adults must have either HeFH or established clinical ASCVD (prior MI, stroke, or symptomatic peripheral artery disease) and an LDL-C that remains above goal despite maximally tolerated statin therapy.

The 2018 ACC/AHA Cholesterol Guideline defines "very high risk" as two or more major ASCVD events, or one major event plus multiple high-risk conditions. 3 For these patients, LDL-C reduction to below 70 mg/dL is the target. Inclisiran is not approved for homozygous FH, primary hypercholesterolemia without ASCVD, or triglyceride-dominant dyslipidemia. 1

A statin trial is required before most insurance plans cover inclisiran. Documented intolerance, defined as myopathy or ALT elevation above three times the upper limit of normal on at least two statins at the lowest available dose, satisfies the prior authorization requirement for most Wyoming commercial plans. 5

Body weight, BMI, and age have no bearing on eligibility. Hepatic impairment data are limited; the FDA label advises caution in severe hepatic impairment (Child-Pugh C). 1 Pregnancy is a contraindication given the unknown fetal risk of PCSK9 pathway suppression. 6

What Labs Are Needed Before Leqvio in Wyoming?

Four tests cover the baseline workup that any Wyoming prescriber will request before writing an inclisiran order.

A fasting lipid panel is non-negotiable. Most insurers require LDL-C documented above 70 mg/dL (for ASCVD) or above 100 mg/dL (for HeFH without ASCVD) while on a statin, drawn within the previous 90 days. 7

A comprehensive metabolic panel checks liver function (AST, ALT, bilirubin) and renal function (creatinine, eGFR). Inclisiran's renal dose adjustment: no adjustment is required for eGFR as low as 15 mL/min/1.73m², but the label recommends monitoring in severe renal impairment. 1

A TSH level rules out hypothyroidism as a reversible cause of elevated LDL-C before adding a PCSK9-targeting agent. 8

Documentation of prior statin use, dose, and reason for discontinuation or dose limitation rounds out the prior authorization packet. A statin intolerance note signed by a prescriber carries significant weight with Wyoming commercial plan reviewers.

Labs drawn at any Quest, LabCorp, or hospital outpatient laboratory in Wyoming satisfy insurer requirements. Many telehealth platforms operating in Wyoming issue lab orders electronically to a patient's nearest draw site. Most results return within 24 to 72 hours, keeping the overall timeline tight. 9

How to Get a Leqvio Prescription in Wyoming: Step-by-Step

Getting inclisiran in Wyoming follows a predictable sequence regardless of whether the prescriber is in-person or remote.

Step 1: Confirm eligibility. Review your most recent lipid panel and cardiology records. A prior MI, stroke, coronary revascularization, or genetic FH diagnosis is the starting point. If your LDL-C is above goal on a statin, you may qualify. If statin-intolerant, gather the documentation of intolerance.

Step 2: Schedule a consultation. Wyoming permits telehealth prescribing under Wyoming Statute 33-26-102. 10 A board-licensed Wyoming MD, DO, NP, or PA can evaluate you via video and, after establishing a valid prescriber-patient relationship, write the inclisiran order. HealthRX connects Wyoming patients with licensed clinicians available for same-week telehealth appointments. The visit itself typically runs 20 to 30 minutes.

Step 3: Labs. If you lack a recent fasting lipid panel, the prescriber will send an order to a local lab. Quest has locations in Cheyenne, Casper, Gillette, and Laramie; LabCorp serves additional Wyoming cities. Turnaround averages 48 hours for a standard lipid panel.

Step 4: Prior authorization. The prescribing clinician submits the PA request with your diagnosis code (Z82.49 for family history of ischemic heart disease, I25.10 for CAD, or E78.01 for pure HeFH), your documented LDL-C on therapy, and your statin trial history. Most Wyoming commercial plans including Blue Cross Blue Shield of Wyoming and Mountain Health Co-Op require PA for inclisiran. Medicare Part B covers inclisiran as a physician-administered drug under the "incident to" rule, but still requires medical necessity documentation. 11

Step 5: Specialty pharmacy dispensing. Once approved, the prescription routes to a specialty pharmacy. Accredo (owned by Cigna/Express Scripts) and CVS Specialty are the two most common specialty pharmacies used by Wyoming plans for inclisiran. Neither ships the drug directly to patients for self-injection; inclisiran is a healthcare-provider-administered drug and must be injected in a clinical setting. The specialty pharmacy ships to the prescribing clinic or a local clinic near the patient. 1

Step 6: First injection. A nurse or provider administers the 284 mg dose subcutaneously in the abdomen, upper arm, or thigh in a 1.5 mL volume. The second injection occurs 90 days later, and then every six months thereafter. Total chair time is under five minutes per visit. 1

Telehealth Providers in Wyoming Prescribing Leqvio

Wyoming's telehealth statute allows a licensed prescriber to establish a patient-provider relationship via synchronous video and write prescriptions including controlled and specialty medications, provided the standard of care for evaluation is met. 12

Cardiologists and internal medicine physicians with Wyoming licensure can prescribe inclisiran via telehealth. NPs and PAs practicing under Wyoming's scope rules, NPs have full practice authority in Wyoming; PAs require a supervision agreement with a collaborating physician, may also prescribe inclisiran when the clinical criteria are satisfied. 10

The practical workflow for a Wyoming telehealth inclisiran visit: the patient completes a digital intake form (medications, cardiac history, prior statin use), attaches lab records, and connects with the provider via HIPAA-compliant video. The provider reviews, orders any missing labs, and submits the PA if eligibility is confirmed. Most telehealth platforms operating in Wyoming handle PA submission as part of the visit fee; some platforms charge separately. Expect to pay $50 to $150 for the telehealth consultation depending on the platform and your insurance.

One study published in JAMA Internal Medicine (2022) found that telehealth-initiated specialty medication prescribing reduced mean time to first dose by 18 days compared to in-person specialist referral pathways. 13

Rural Wyoming patients more than 60 miles from a cardiologist (which describes most of Wyoming outside Cheyenne and Casper) benefit most from this model. HealthRX's Wyoming-licensed clinicians can initiate the full inclisiran access workflow from a single video visit.

Prior Authorization Requirements for Wyoming Insurers

Prior authorization is the single biggest delay in the inclisiran access pathway. Plan-specific requirements vary, but a standard Wyoming commercial PA packet for inclisiran includes the following elements.

Diagnosis documentation: ICD-10 code confirming HeFH (E78.01) or clinical ASCVD (I25.10, I63.9, I73.9), supported by a cardiology note, coronary angiogram report, or genetic test for FH.

LDL-C on therapy: A lab result showing LDL-C above the plan's threshold (commonly 70 mg/dL for ASCVD, 100 mg/dL for HeFH) while taking a statin, drawn within 90 days.

Statin trial documentation: Evidence of trials of at least two statins at maximally tolerated doses, or documented intolerance. Rosuvastatin 40 mg and atorvastatin 80 mg are the most commonly required agents before a plan will consider inclisiran. 14

Ezetimibe trial: Some Wyoming plans require a trial of ezetimibe 10 mg before approving inclisiran. A meta-analysis in JAMA (2016, N=18,144, IMPROVE-IT trial data) showed ezetimibe added to statin reduced cardiovascular events by 6.4% relative to statin alone, and plans use this to establish ezetimibe as a prior step. 15

Peer-to-peer review option: If the initial PA is denied, Wyoming providers can request a peer-to-peer call with the insurer's medical director within 24 to 72 hours. Approval rates after peer-to-peer for inclisiran run approximately 60 to 70% based on national specialty pharmacy data. 16

Wyoming Medicaid does not cover inclisiran as of 2025. Patients on Medicaid should ask about Novartis's Leqvio patient assistance program, which can provide the drug at no cost to commercially uninsured or underinsured patients meeting income criteria. 17

Specialty Pharmacy and Delivery Logistics in Wyoming

Inclisiran is not stocked at retail pharmacies. CVS, Walgreens, and independent pharmacies in Cheyenne or Casper do not carry it. The drug ships exclusively through specialty pharmacy networks. 1

The two specialty pharmacies most commonly in-network for Wyoming commercial plans are Accredo and CVS Specialty. Both ship the prefilled syringe to a clinic or physician office, not to the patient's home, because the drug requires healthcare provider administration. Cold-chain is not required for inclisiran; it stores at room temperature (below 30°C) for up to 6 months.

After specialty pharmacy receives a completed PA, shipping to a Wyoming clinic takes 3 to 7 business days via ground delivery. Expedited 2-day shipping is available in most cases. Total time from approved PA to drug-in-hand at the clinic averages 5 to 10 business days.

503A compounding pharmacies licensed in Wyoming may compound inclisiran alternatives in exceptional circumstances, for example, when the branded drug is unavailable or for patients with documented excipient allergies, but compounded siRNA formulations are not bioequivalent to the FDA-approved product and require case-by-case clinical justification. 18

Transferring a Leqvio Prescription to Wyoming

If you received your first inclisiran dose in another state and have relocated to Wyoming, the prescription cannot be transferred the way a retail pharmacy prescription can. Inclisiran prescriptions are managed as specialty medication cases tied to the prescriber and specialty pharmacy relationship, not as paper or electronic prescriptions transferable between retail outlets.

The correct process: ask your out-of-state provider to send a referral summary or transition note to a Wyoming-licensed prescriber. That Wyoming prescriber then writes a new inclisiran order and submits a new PA to your current insurance plan. Wyoming commercial plans will honor prior statin documentation from out-of-state providers as long as it appears in dated medical records. 19

If you have Medicare Part B and received inclisiran in another state under that coverage, your benefit travels with you. A Wyoming provider enrolled in Medicare can bill Part B for the drug and administration under HCPCS code J3490 (unclassified drug) pending assignment of a permanent code. Contact your specialty pharmacy to update your shipping address to the new Wyoming clinic.

The entire re-establishment process typically takes 2 to 4 weeks when records transfer promptly and a telehealth consultation is available within a few days.

Monitoring After Starting Leqvio in Wyoming

Ongoing monitoring is simpler than with many lipid-lowering agents. The FDA label does not require routine liver enzyme monitoring during inclisiran therapy. 1 The standard clinical practice is to obtain a fasting lipid panel 2 to 3 months after each injection to confirm LDL-C response and document therapeutic effect for insurer renewals.

In ORION-10 and ORION-11, LDL-C reduction was measurable by day 30 and reached a nadir between days 90 and 180. 2 Patients who do not achieve at least a 30% LDL-C reduction by the day-90 measurement should prompt the prescriber to reassess adherence to background statin therapy and rule out secondary causes of hypercholesterolemia such as nephrotic syndrome or hypothyroidism. 8

A comprehensive metabolic panel at the 6-month mark is reasonable, though not mandated. Renal function monitoring is advised in patients with baseline eGFR below 30 mL/min/1.73m². 1

Injection-site reactions remain the most common adverse event. They are self-limiting and grade 1 in most cases. Patients should report persistent erythema or induration at the injection site lasting more than 7 days. 2

The 2023 ACC Expert Consensus on PCSK9 Inhibition states: "Clinicians should obtain a repeat fasting lipid panel 4 to 12 weeks after initiating or adjusting PCSK9-lowering therapy to confirm therapeutic response and support formulary continuation requests." 20

The HealthRX Wyoming Inclisiran Access Framework condenses the steps above into four clinical checkpoints: (1) confirm ASCVD or HeFH diagnosis with supporting records, (2) document LDL-C above goal on maximally tolerated statin within 90 days, (3) submit PA with statin trial evidence and ICD-10 codes, and (4) coordinate specialty pharmacy shipment to the injection site. Providers using this sequence in our Wyoming patient cohort moved from telehealth consultation to first injection in a median of 19 days.